The *Diagnostic and Statistical Manual of Mental Disorders* (Fifth Edition) (DSM-5) ([@bibr2-0004867415575774]) has reclassified pathological gambling as an addiction and related disorder along with alcohol and substance use disorders, and renamed it gambling disorder. In many jurisdictions, however, the term problem gambling is employed to describe all forms of gambling, including the more severe classification of pathological gambling, that lead to adverse consequences for the gambler, others, or the community ([@bibr57-0004867415575774]). There is substantial evidence that problem gambling can result in many adverse consequences, including impaired mental and physical health, relationship and family dysfunction, financial problems, employment difficulties and legal issues ([@bibr60-0004867415575774]). Problem gambling has also been consistently associated with a range of co-morbid psychiatric conditions formerly known as Axis I disorders in the DSM-IV, including alcohol and other substance use disorders, mood and anxiety disorders, and other impulse control disorders ([@bibr12-0004867415575774]; [@bibr51-0004867415575774]; [@bibr59-0004867415575774]; [@bibr76-0004867415575774]).

Internationally, the co-occurrence between problem gambling and co-morbid psychiatric conditions has been empirically examined in both epidemiological and clinical samples. By randomly sampling the general population, epidemiological studies provide results that are representative of problem gamblers in the community. They are, however, generally only able to determine the co-occurrence of problem gambling with highly prevalent co-morbid disorders because they yield very small numbers of problem gamblers ([@bibr51-0004867415575774]; [@bibr76-0004867415575774]). A systematic review and meta-analysis of co-morbid disorders in population-representative samples of problem gamblers revealed high rates of psychiatric disorders, including nicotine dependence (60%), alcohol and substance use disorders (58%), mood disorders (38%) and anxiety disorders (37%) ([@bibr51-0004867415575774]).

Although these population-representative studies provide important information about the prevalence of co-morbidity in problem gamblers living in the community, caution is required in generalising results from these samples to treatment-seeking populations given emerging evidence that treatment-seeking problem gamblers display more severe gambling problems and a greater variety and intensity of co-morbid psychiatric disorders compared with their non-treatment seeking counterparts ([@bibr12-0004867415575774]; [@bibr65-0004867415575774]; [@bibr68-0004867415575774]). Although they generally employ non-random samples, treatment-seeking studies generally comprise larger samples of problem gamblers, which allows for the investigation of lower prevalence co-morbid disorders and an investigation of how the level of gambling severity co-varies with co-morbid disorders ([@bibr76-0004867415575774]).

To date, only narrative reviews of psychiatric co-morbidity in treatment-seeking problem gambling samples are available ([@bibr59-0004867415575774]; [@bibr68-0004867415575774]; [@bibr76-0004867415575774]). Unfortunately, these reviews are not based on all of the available evidence, generally only explore the prevalence of high prevalence disorders, such as mood disorders, anxiety disorders and substance use disorders, and are unable to explore the degree to which prevalence estimates of co-morbidity fluctuate as a function of clinical and methodological considerations, such as gambling severity. They are also generally characterised by a lack of quality and risk of bias appraisal, a failure to identify the relative strength and reliability of the evidence for each of the psychiatric co-morbid disorders, and a lack of clarity about the generalizability of the findings to all treatment-seeking problem gamblers. It is therefore important that a systematic review of psychiatric co-morbidity in treatment-seeking problem gambling samples is conducted to redress the limitations of these narrative reviews.

The findings relating to psychiatric co-morbidity in treatment-seeking samples of problem gamblers are important in understanding individual treatment needs and outcomes ([@bibr51-0004867415575774]). There is accumulating evidence that the presence of co-morbid disorders in treatment-seeking problem gamblers is associated with an increased severity of gambling behaviour, gambling-related consequences, psychiatric symptoms, impulsivity and other psychosocial difficulties ([@bibr21-0004867415575774]; [@bibr25-0004867415575774]; [@bibr35-0004867415575774]; [@bibr48-0004867415575774]). The presence of co-morbid psychiatric conditions therefore has implications for individual case formulation, treatment planning and selection, the proposed objectives and expectations of the selected treatment, and the length of treatment. Psychiatric co-morbidity may also affect an individual's compliance with treatment, the success of treatment, the likelihood of relapse and the number of treatment attempts ([@bibr35-0004867415575774]; [@bibr39-0004867415575774]; [@bibr46-0004867415575774]; [@bibr76-0004867415575774]). Although there are equivocal findings, there is some evidence that problem gamblers with co-morbid psychiatric symptoms have poorer outcomes and higher rates of drop-out for psychological interventions than those without co-morbid disorders ([@bibr18-0004867415575774]; [@bibr32-0004867415575774]; [@bibr55-0004867415575774]).

The findings from both community-representative and treatment-seeking studies suggest that prevalence estimates of psychiatric co-morbidity in treatment-seeking problem gamblers vary widely. There is therefore a need to explore the methodological and clinical factors that may explain these variations in estimates. The heterogeneity in prevalence estimates may be due to differences in the characteristics of the sample or patient population, measurement factors, treatment factors or methodological considerations ([@bibr3-0004867415575774]; [@bibr8-0004867415575774]; [@bibr17-0004867415575774]; [@bibr51-0004867415575774]). There is some evidence that pathological gamblers display higher rates of co-morbidity than problem gamblers ([@bibr51-0004867415575774]) and that self-report inventories generally produce higher rates of co-morbidity than clinical interviews ([@bibr37-0004867415575774]; [@bibr46-0004867415575774]). There is also some indication that gamblers attending residential services report higher rates of co-morbid conditions than those attending outpatient services ([@bibr5-0004867415575774]; [@bibr47-0004867415575774]; [@bibr59-0004867415575774]) and that rates may be affected by region ([@bibr51-0004867415575774]; [@bibr68-0004867415575774]).

Aims {#section5-0004867415575774}
====

The aims of the current paper are to: (1) evaluate the prevalence of current and lifetime co-morbid psychiatric disorders that are listed as Axis I diagnoses in the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) ([@bibr1-0004867415575774]) among problem gamblers seeking treatment using meta-analytic techniques; (2) explore the factors that explain the variability in the prevalence estimates of these co-morbid conditions using sub-group analyses; and (3) examine whether findings were robust to the quality of the study methodologies using sensitivity analyses. Prevalence estimates of co-morbid disorders that are listed as Axis II diagnoses (personality disorders) in the DSM-IV are reported in a separate article ([@bibr14-0004867415575774]).

Method {#section6-0004867415575774}
======

The methodology employed in this review is compliant with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) ([@bibr56-0004867415575774]) and the guidelines for the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) ([@bibr70-0004867415575774]).

Search strategy {#section7-0004867415575774}
---------------

A systematic search was conducted for studies that provided prevalence estimates of psychiatric disorders in individuals seeking psychological or pharmacological treatment for problem gambling. This search procedure comprised a number of strategies. Electronic databases, including Medline, PsycInfo, EMBASE and CINAHL, were searched. A number of specific journals that were not indexed in the electronic databases were also manually examined. These included *Gambling Research* (2003 onwards), *International Gambling Studies* (2001--2003) and *Journal of Gambling Issues* (2000--2006). Finally, the reference lists of all included studies and several narrative reviews were also searched manually. The search was limited to peer-reviewed published studies so as to ensure a rigorous methodological standard of included research. The search terms used incorporated a combination of keywords and wildcards relating to problem gambling and treatment. It did not include keywords relating to specific co-morbid psychiatric conditions. The search was restricted to articles published from January 1990 to August 2011, consistent with the development of the first standardised and validated assessment instrument for the identification of problem gambling in clinical settings ([@bibr50-0004867415575774]). A detailed description of the search strategy is provided in Appendix A.

Inclusion criteria {#section8-0004867415575774}
------------------

Studies were considered eligible for the current review if they met the following inclusion criteria: (1) the study sample comprised adults recruited from treatment services where problem gambling was the index condition or clinical trials of gambling treatment for problem gamblers recruited from these services or the community. Gambling treatment included any treatment primarily delivered for the index condition of problem gambling, including psychological treatments (including self-help and Gamblers Anonymous) or pharmacological treatments. These treatments could be delivered in any setting, including specialist gambling services, addiction services, impulse control disorders services or mental health services. They could be delivered in any modality, including outpatient, residential, online or telephone; (2) the study provided an estimate of the prevalence of one or more psychiatric conditions that are listed as diagnoses in the DSM-IV identified using standardised and validated self-report measures with clinical cut-off scores or clinical interviews based on the DSM-IV or previous versions of the DSM; (3) the full-text report was available in English; and (4) the study was reported in a complete manuscript outlining original work published in a peer-reviewed journal from 1990 to 2011.

Studies were not eligible if they: (1) applied inclusion or exclusion criteria (for participant admission to the study) based on DSM-IV diagnostic conditions (e.g. a clinical trial that excluded participants on the basis of all current Axis I disorders). Studies that excluded participants on the basis of conditions that preclude completion of assessment measures or treatment (e.g. cognitive impairment, such as intellectual disability, delirium, dementia or amnesia; or acute/uncontrolled psychiatric disorders, such as psychotic disorder or suicidality) were included; (2) assessed clinical characteristics that are not listed as diagnostic conditions in the DSM-IV (e.g. impulsivity, suicidality, personality traits, substance use, sensation seeking); or (3) failed to provide sufficient data (e.g. providing only means or standard deviations, combining prevalence estimates for multiple co-morbid disorders, or failing to identify the measure employed). Where there were multiple articles based on the same sample: (a) only the study with the larger sample was included when a larger sample in one study subsumed a smaller sample in another study; (b) only the study with the most focus on co-morbid disorders was reported when two studies reported the same prevalence data from the same sample; and (c) both studies were included and are listed together in the table of included studies ([Table 1](#table1-0004867415575774){ref-type="table"}) when two studies with the same sample reported prevalence data for different disorders. Data from each sample was included only once in any given analysis.

###### 

Characteristics of included studies.

  Study                           Year        Country       Sample size (*n*)   Average age (years)   Gender (% male)   Treatment facility (outpatient, residential)   Treatment service (gambling, addictions, impulse control, mental health)   Treatment type (psychological, pharmacological, GA)   Gambling severity (pathological, problem)   Measure of problem gambling   Problematic gambling activity (mixed, EGMs)   Co-morbidity measures (interview, self-report)
  ------------------------------- ----------- ------------- ------------------- --------------------- ----------------- ---------------------------------------------- -------------------------------------------------------------------------- ----------------------------------------------------- ------------------------------------------- ----------------------------- --------------------------------------------- ------------------------------------------------
  Battersby et al.                2006        Australia     43                  41.5                  70                Outpatient                                     Gambling                                                                   Psychological                                         Pathological                                Diagnostic criteria           NR                                            Self-report
  Breen and Zimmerman             2002        US            44                  46.9                  61                Outpatient                                     Gambling                                                                   Combined                                              Pathological                                Diagnostic criteria           Mixed                                         Interview
  Cavedini et al.                 2002        Italy         20                  38.5                  95                Outpatient                                     Gambling                                                                   NR                                                    Pathological                                Diagnostic criteria           NR                                            Interview
  Dannon et al.                   2006        Israel        78                  NR^a^                 54                Outpatient                                     Gambling                                                                   NR                                                    Pathological                                Diagnostic criteria           NR                                            Interview
  Echeburua et al.                2011        Spain         103                 43.1                  51                Outpatient                                     Gambling                                                                   Psychological                                         Pathological                                Diagnostic criteria           Mixed                                         Interview
  Goudriaan et al.                2010        Netherlands   17                  35.3                  100               NR                                             Addiction                                                                  NR                                                    Problem                                     DIS                           NR                                            Interview
  Grall-Bronnec et al.            2011        France        84                  41.8                  86                NR                                             Addiction                                                                  NR                                                    Problem                                     Diagnostic criteria           Mixed                                         Interview and self-report
  Granero et al.                  2009        Spain         286                 45.4                  50                NR                                             Gambling                                                                   NR                                                    Pathological                                DQ-PG                         Mixed                                         Interview
  Grant and Grosz                 2004        US            14                  64.9                  57                Outpatient                                     Gambling                                                                   Combined                                              Pathological                                Diagnostic criteria           NR                                            Interview
  Grant and Kim                   2002        US            50                  47.7                  50                Outpatient                                     Gambling                                                                   Combined                                              Pathological                                Diagnostic criteria           NR                                            Interview
  Grant and Kim                   2003        US            96                  46.7                  54                Outpatient                                     impulse control                                                            NR                                                    Pathological                                Diagnostic criteria           NR                                            Interview
  Grant et al.                    2009        US            322                 48.3                  42                Outpatient                                     Gambling                                                                   Psychological or pharmacological                      Pathological                                SCI-PG                        Mixed                                         Interview
  Grant et al.                    2008        US            465                 47.6                  46                Outpatient                                     Gambling                                                                   Psychological or pharmacological                      Pathological                                SCI-PG                        Mixed                                         Interview
  Grant and Potenza               2006        US            105                 46.1                  100               Outpatient                                     Gambling                                                                   Psychological or pharmacological                      Pathological                                SCI-PG                        NR                                            Interview
  Ibanez et al.                   2001        Spain         69                  NR ^a^                68                NR                                             Gambling                                                                   NR                                                    Pathological                                Diagnostic criteria           NR                                            Interview
  Jimenez-Murcia et al.           2009        Spain         498                 41.5                  88                NR                                             Gambling                                                                   NR                                                    Pathological                                Diagnostic criteria           Mixed                                         Interview
  Kausch / Kausch                 2003        US            113                 48.9                  91                Residential                                    Gambling                                                                   NR                                                    Pathological                                Diagnostic criteria           NR                                            Interview
  Kausch                          2004        US            135                 51.9                  93                Residential                                    Gambling                                                                   NR                                                    Pathological                                Diagnostic criteria           Mixed                                         Interview
  Kennedy et al.                  2005        Japan         35                  33.2                  74                NR                                             Gambling                                                                   Psychological                                         Pathological                                Diagnostic criteria           Mixed                                         Interview
  Kerber et al.                   2008        US            40                  62.0                  63                Outpatient                                     Gambling                                                                   Psych or GA                                           Problem                                     SOGS/NODS                     NR                                            Interview
  Korman et al.                   2008        Canada        42                  47.6                  86                Outpatient                                     addiction/mental health                                                    Psychological                                         Problem                                     PGSI                          NR                                            Interview
  Kroeber                         1992        Germany       43                  32.2                  98                Either                                         Gambling                                                                   Psychological                                         Problem                                     Diagnostic criteria           Mixed                                         Interview
  Kruedelbach et al.              2006        US            162                 46.7                  98                Residential                                    Gambling                                                                   NR                                                    Pathological                                Diagnostic criteria           Mixed                                         Interview
  Ladouceur et al.                2006        Canada        233                 42.8                  73                Either                                         Gambling                                                                   Psychological                                         Pathological                                Diagnostic criteria           NR                                            Interview
  Ledgerwood and Petry            2006        US            149                 47.6                  48                NR                                             Gambling                                                                   NR                                                    Problem                                     NODS                          NR                                            Self-report
  Lee et al./Teo et al.           2007        Singapore     300                 40.7                  88                Either                                         Gambling                                                                   Psychological                                         Pathological                                Diagnostic criteria           Mixed                                         Interview
  Maccallum and Blaszczynski      2002        Australia     75                  37.7                  64                Outpatient                                     Gambling                                                                   Psychological                                         Pathological                                Diagnostic criteria           EGMs                                          Interview
  Martins et al.                  2004        Brazil        156                 42.7                  50                Outpatient                                     Gambling                                                                   Psychological                                         Pathological                                Diagnostic criteria           NR                                            Interview
  Patterson et al.                2006        US            18                  45.0                  NR ^a^            Residential                                    Gambling                                                                   NR                                                    Pathological                                SOGS                          NR                                            Interview
  Sander and Peters               2009        Germany       281                 38.2                  88                Residential                                    Gambling                                                                   Psychological                                         Pathological                                Diagnostic criteria           Mixed                                         Interview
  Smith et al.                    2010        Australia     127                 43.1                  54                Outpatient                                     Gambling                                                                   Psychological                                         Problem                                     VGS                           Mixed                                         Self-report
  Specker et al./Specker et al.   1995/1996   US            40                  41.1                  63                Outpatient                                     Gambling                                                                   NR                                                    Pathological                                Diagnostic criteria           Mixed                                         Interview
  Stinchfield and Winters         2001        US            592                 39.0                  59                Outpatient                                     Gambling                                                                   Psychological                                         Pathological                                Diagnostic criteria           Mixed                                         Interview
  Tavares and Gentil              2007        Brazil        40                  40.5                  50                NR                                             Gambling                                                                   NR                                                    Pathological                                Diagnostic criteria           NR                                            Interview
  Tavares et al.                  2003        Brazil        140                 42.8                  50                Outpatient                                     Gambling                                                                   NR                                                    Pathological                                Diagnostic criteria           Mixed                                         Interview
  Zimmerman et al.                2010        US            210                 39.9                  56                Outpatient                                     Gambling                                                                   NR                                                    Problem                                     NR                            NR                                            Interview

![](10.1177_0004867415575774-table1)

DIS: Diagnostic Interview Schedule; DQ-PG: Diagnostic Questionnaire for Pathologic Gambling; GA: Gamblers Anonymous; NODS: NORC Diagnostic Screen for Gambling Disorders; NR: Not reported; PGSI: Problem Gambling Severity Index; SCI-PG: Structured Clinical Interview for Pathologic Gambling; SOGS: South Oaks Gambling Screen; VGS: Victorian Gambling Screen.

Search results {#section9-0004867415575774}
--------------

A PRISMA flow diagram of the search results is displayed in [Figure 1](#fig1-0004867415575774){ref-type="fig"}. The search identified 3,587 articles after duplicate records were removed. The title and abstracts of these records were independently reviewed for inclusion by two separate authors. The full-texts of the 257 articles that were deemed potentially eligible were retrieved and 42 studies, published in 46 articles, met the inclusion criteria. Of these, 36 studies, published in 39 articles, provided prevalence estimates for DSM-IV Axis I disorders and are reported in this article. Fifteen studies, published in 16 articles, provided prevalence estimates for Axis II disorders (personality disorders) and are reported separately ([@bibr14-0004867415575774]).

![Flow diagram of search results.](10.1177_0004867415575774-fig1){#fig1-0004867415575774}

Data extraction {#section10-0004867415575774}
---------------

The first author (ND) extracted data from the included studies. In most cases, the prevalence estimate was available from the primary study. In other instances, it was necessary to combine findings reported for separate groups (e.g. men and women) to derive total sample prevalence rates. Prevalence estimates were reported for co-morbid psychiatric disorders that had three or more estimates available. To ensure the data extraction was accurate, one-third of the articles (33%; *k*=15) were randomly selected for double data extraction by two independent reviewers (AJ and KF). The inter-rater agreement across the multiple reviewers was 98.2%. Discrepancies were resolved through group discussion with third reviewer as arbiter.

Data analysis {#section11-0004867415575774}
-------------

### Meta-analyses {#section12-0004867415575774}

Findings from primary studies were synthesised in meta-analyses using the Comprehensive Meta-Analysis (CMA) program (Version 2.0) ([@bibr9-0004867415575774]). A series of separate meta-analyses were conducted to provide the current best prevalence estimate of each co-morbid disorder, all using a 'random effects' model. When differences across studies are attributed mainly to sampling error, a random-effects analysis provides an estimate of the weighted mean effect and a 95% confidence interval (CI) (that indicates the precision of this estimate). The *I^2^* statistic indicates the amount of variation across studies due to true differences (heterogeneity) rather than chance (sampling error), and is expressed as a proportion (%) of the total observed variance. This statistic is in the range of 0--100%, whereby values of 25%, 50% and 75% are tentatively suggested to represent low, moderate and high levels of heterogeneity, respectively ([@bibr31-0004867415575774]).

### Subgroup analyses {#section13-0004867415575774}

The observation of heterogeneity across studies precipitated consideration of study characteristics that could explain these between-study differences. Subgroup analyses were conducted to examine potential sources of heterogeneity for co-morbid disorders that had a sufficient number of primary studies available (10 or more). This involved the production of separate estimates of summary effect (with 95% CIs) for subgroups of studies. Significant differences were assumed when the 95% CIs did not overlap ([@bibr34-0004867415575774]). Based on previous literature, several study characteristics potentially explaining the observed variance were identified before the commencement of analysis. These were: (1) gambling problem severity (pathological gamblers compared to problem gamblers); (2) the measure of co-morbidity employed (clinician-administered interviews compared to self-report questionnaires); (3) the type of treatment facility (outpatient treatment services only compared to residential treatment services only); and (4) the jurisdiction in which the study was conducted (treatment services located in the US compared to treatment services located in Europe); other jurisdictions were not included in the subgroup analyses due to an insufficient number of studies.

### Risk of bias assessment {#section14-0004867415575774}

The use of quality scoring in meta-analyses of observational studies is controversial and generally not recommended ([@bibr31-0004867415575774]; [@bibr70-0004867415575774]; [@bibr75-0004867415575774]) because scores constructed in an ad hoc fashion may lack demonstrated validity, and results may not be associated with quality ([@bibr38-0004867415575774]). A components approach was therefore adopted to assess risk of bias in this systematic review, whereby each study was rated on individual criteria that reflect the methodological risk of bias ([@bibr31-0004867415575774]; [@bibr75-0004867415575774]). These criteria explicitly evaluated risk of selection bias (use of an appropriate comparison group, volunteer/selection bias, and observation of treatment in naturalistic settings settings), performance bias (concurrent treatment restriction), detection bias (valid and reliable gambling measure) and reporting biases (industry sponsorship) ([@bibr31-0004867415575774]; [@bibr75-0004867415575774]). Studies that failed to consecutively or randomly recruit participants and/or were clinical trials were classified as having a non-representative sampling bias. With a view to contextualising this information, studies were also examined for the degree to which the measurement of co-morbidity was the stated purpose of the study. These criteria were reviewed by pairs of bias reviewers with a third reviewer serving as arbiter of conflicts. The inter-rater agreement across the multiple reviewers for the assessment of bias criteria was 95.1%.

### Sensitivity analyses {#section15-0004867415575774}

As recommended by experts in the area of risk of bias assessment ([@bibr70-0004867415575774]; [@bibr75-0004867415575774]), sensitivity analyses were conducted to examine whether findings were robust to the quality of the methodological approaches of the included studies. The sensitivity analyses were sequentially limited to studies with representative samples: (1) observational studies of treatment in naturalistic settings (versus clinical trials which were excluded); and (2) random samples or recruitment of consecutive admissions (versus convenience samples comprising research participants who have volunteered to participate \[self-selected samples\] or studies failing to indicate the sampling strategies which were excluded). The data analytic approach employed in this study for each sensitivity analysis, whereby the meta-analysis was undertaken twice: first, including all studies and second, only including those that are definitely known to be eligible, is recommended by the Cochrane collaboration ([@bibr30-0004867415575774]). These analyses were conducted for all types of co-morbidity, irrespective of number of studies.

Study and sample characteristics {#section16-0004867415575774}
--------------------------------

The characteristics of the included studies reporting prevalence estimates for DSM-IV Axis I disorders are presented in [Table 1](#table1-0004867415575774){ref-type="table"}. The sizes of the samples were in the range of 14--592 (*M*=145.1, *SD*=143.4, median=100). The average age of study participants was in the range of 33.2--64.9 years (*M*=43.0, *SD*=6.7, median=44) and the proportion of men in the samples was in the range of 42--100% (*M*=62.5%, *SD*=18.9, median=69). Most samples were restricted to pathological gamblers only (77.8%) measured via diagnostic criteria (69.4%) who were treated in gambling services (88.9%). Most samples were recruited from the US (44.4%) and Europe (25.0%) and most studies (94.4%) were published between 2001 and 2011. Co-morbidity measures were predominantly clinician-administered interviews (88.9%), with few studies using self-report measures (11.1%). Less commonly reported data were the problematic gambling activity (47.2% mixed, 2.8% electronic gaming machines only, 50.0% not reported), the type of treatment facility (52.8% outpatient facilities, 13.9% residential facilities, 11.1% recruitment from multiple types of facilities, 22.2% not reported), and the type of treatment delivered (33.3% psychological treatments, 8.3% combined treatments, 11.1% recruitment from multiple types of treatments, 47.2% not reported).

Approximately one-third of studies (*k*=11, 30.6%) indicated they excluded participants who were unable to complete assessment measures or treatment. However, with the exception of one study that excluded 23 participants on the basis of an 'unstable mental state' ([@bibr66-0004867415575774]), these studies either failed to report the number of participants excluded on this basis (*k*=8) or reported that few (none or one) participants were excluded on this basis (*k*=2). A series of subgroup analyses revealed that there were no significant differences in prevalence estimates between studies that excluded participants on this basis and those that did not.

Results {#section17-0004867415575774}
=======

Meta-analyses {#section18-0004867415575774}
-------------

### Current DSM-IV Axis I disorders {#section19-0004867415575774}

Prevalence estimates for any current DSM-IV Axis I disorder were provided by five studies ([Table 2](#table2-0004867415575774){ref-type="table"}). There was a weighted mean effect of 74.8% (95% CI 36.5--93.9) with very high between-study heterogeneity.

###### 

Prevalence of any current Axis I disorder in treatment-seeking problem gamblers.

  Study                        Co-morbidity measure   Any current Axis I disorder
  ---------------------------- ---------------------- -----------------------------
  [@bibr29-0004867415575774]   SCID (DSM-IV)          21.0%
  [@bibr41-0004867415575774]   Clinical diagnosis     93.0%
  [@bibr58-0004867415575774]   MINI                   100%
  [@bibr72-0004867415575774]   SCAN                   81.0%
  [@bibr68-0004867415575774]   SCID (DSM-III-R)       54.0%
  Summary effect (95% CI)                             74.8% (36.5--93.9)
  *I^2^* (%)                                          95.88

![](10.1177_0004867415575774-table2)

MINI: Mini International Neuropsychiatric Interview; SCAN: Schedules for Clinical Assessment in Neuropsychiatry; SCID (DSM-III-R): Structured Clinical Interview for DSM-III-R; SCID (DSM-IV): Structured Clinical Interview for DSM-IV.

#### Substance use disorders {#section20-0004867415575774}

Prevalence estimates for substance use disorders were provided by 26 studies ([Table 3](#table3-0004867415575774){ref-type="table"}). There were weighted mean effects of 22.2% (95% CI 36.5--93.9) for any alcohol or substance use disorder, 21.2% (95% CI 5.6--28.1) for any alcohol use disorder and 7.0% (95% CI 1.7--24.9) for any substance (non-alcohol) use disorder. Specifically, the highest weighted mean effect was for nicotine dependence (56.4%, 95% CI 35.7--75.2) followed by alcohol abuse (18.2%, 95% CI 13.4--24.2), alcohol dependence (15.2%, 95% CI 10.2--22.0) and cannabis use disorder (11.5%, 95% CI 4.8--25.0). There was moderate to very high between-study heterogeneity for current substance use disorders.

###### 

Prevalence of co-morbid current substance use disorders in treatment-seeking problem gamblers.

  Study                                                   Co-morbidity measure                 Any alcohol or substance use disorder   Any alcohol use disorder   Alcohol abuse        Alcohol dependence   Any substance (non-alcohol) use disorder   Substance (non-alcohol) abuse   Substance (non-alcohol) dependence   Nicotine dependence   Cannabis use disorder
  ------------------------------------------------------- ------------------------------------ --------------------------------------- -------------------------- -------------------- -------------------- ------------------------------------------ ------------------------------- ------------------------------------ --------------------- -----------------------
  [@bibr13-0004867415575774]                              Clinical diagnosis                                                                                      11.5%                                                                                5.1%                                                                                       
  [@bibr19-0004867415575774]                              Clinical diagnosis                                                                                                                                                                           20.4%                                                                                      
  [@bibr22-0004867415575774]                              Clinical diagnosis                                                                                      12.7%                                                                                8.6%                                                                                       
  [@bibr23-0004867415575774]                              Clinical diagnosis                                                                                                                                0%                                         0%                              0%                                                         
  [@bibr24-0004867415575774]                              Clinical diagnosis                                                           14.0%                                                                                                                                                                                                      
  [@bibr27-0004867415575774]                              SCID (DSM-IV)                                                                5.2%                                                                 0%                                         0%                              0%                                                         
  [@bibr27-0004867415575774]                              SCID (DSM-IV)                        23.7%                                   20.2%                                                                6.9%                                                                                                                                  
  [@bibr29-0004867415575774]                              SCID (DSM-IV)                        10.5%                                                                                                                                                                                                                                              
  [@bibr35-0004867415575774]                              SCID (DSM-III-R)                                                             23.2%                                                                                                           2.9%                                                                                       
  [@bibr37-0004867415575774]                              Clinical diagnosis (DSM-IV)          10.7%                                                                                                                                                                                                                                              
  [@bibr39-0004867415575774]                              Clinical diagnosis                                                                                      32.7%                                                                                                                                                                           
  [@bibr42-0004867415575774]                              Clinical diagnosis                   40.0%                                                                                                                                                                                                                                              
  [@bibr43-0004867415575774]                              MINI                                                                                                                         32.5%                                                                                                                                                      
  [@bibr44-0004867415575774]                              Clinical diagnosis                   45.2%                                   38.1%                                                                                                                                                                                                      19.0%
  [@bibr45-0004867415575774]                              Clinical diagnosis (DSM-III-R)       47.8%                                   34.9%                      30.2%                4.3%                                                                                                                                                       
  [@bibr47-0004867415575774]                              MCMI-III                                                                                                24.0%                                                                                                                                                                           
  [@bibr49-0004867415575774]/[@bibr74-0004867415575774]   SCID (DSM-IV)                                                                10.3%                                                                7.3%                                                                                                                                  
  [@bibr52-0004867415575774]                              CIDI                                                                         24.0%                      16.0%                8.0%                                                                                                                                 37.3%                 10.6%
  [@bibr54-0004867415575774]                              SCAN                                                                                                    10.9%                                                                                                                                                                           
  [@bibr58-0004867415575774]                              MINI                                 27.7%                                   27.7%                      16.7%                11.1%                11.1%                                      11.1%                           0%                                                         
  [@bibr64-0004867415575774]                              Clinical diagnosis (DSM-IV/ICD-10)   19.9%                                   34.9%                                                                54.8%                                                                                                                                 
  [@bibr66-0004867415575774]                              AUDIT                                                                        30.7%                      16.5%                14.2%                                                                                                                                                      
  [@bibr68-0004867415575774]                              SCID (DSM-III-R)                     7.5%                                    7.5%                                                                 0%                                         0%                              0%                                                         0%
  [@bibr69-0004867415575774]                              Clinical diagnosis (DSM-III-R)       16.0%                                                                                                                                                                                                                                              
  [@bibr72-0004867415575774]                              SCAN                                                                                                                         20.0%                                                                                           5.0%                                 62.5%                 
  [@bibr73-0004867415575774]                              SCAN                                                                                                                         16.4%                                                                                           12.1%                                68.6%                 
  Summary effect (95% CI)                                                                      22.2% (16.1--29.8)                      21.2% (15.6--28.1)         18.2% (13.4--24.2)   15.2% (10.2--22.0)   7.0% (1.7--24.9)                           6.6% (3.3--12.7)                4.2% (1.5--11.4)                     56.4% (35.7--75.2)    11.5% (4.8--25.0)
  *I^2^* (%)                                                                                   89.68                                   86.62                      79.02                61.52                97.53                                      72.13                           51.21                                89.49                 58.02

![](10.1177_0004867415575774-table3)

AUDIT: Alcohol Use Disorders Identification Test; CIDI: Composite International Diagnostic Interview; MCMI-III: Millon Clinical Multiaxial Inventory-III; MINI: Mini International Neuropsychiatric Interview; SCAN: Schedules for Clinical Assessment in Neuropsychiatry; SCID (DSM-III-R): Structured Clinical Interview for DSM-III-R; SCID (DSM-IV): Structured Clinical Interview for DSM-IV.

#### Mood disorders {#section21-0004867415575774}

Prevalence estimates for mood disorders were provided by 22 studies ([Table 4](#table4-0004867415575774){ref-type="table"}). There was a weighted mean effect of 23.1% (95% CI 14.9--34.0) for any mood disorder. Specifically, there were weighted mean effects of 29.9% (95% CI 20.5--41.3) for major depressive disorder, 8.8% (95% CI 4.4--17.1) for bipolar disorder and 6.7% (95% CI 4.8--9.2) for dysthymic disorder. There was high between-study heterogeneity for all current mood disorders, except dysthymic disorder, which had very low between-study heterogeneity.

###### 

Prevalence of co-morbid current mood disorders in treatment-seeking problem gamblers.

  Study                                                    Co-morbidity measure                 Any mood disorder    Major depressive disorder   Dysthymic disorder   Bipolar disorder
  -------------------------------------------------------- ------------------------------------ -------------------- --------------------------- -------------------- ------------------
  [@bibr5-0004867415575774]                                BDI                                                       48.8%                                            
  [@bibr13-0004867415575774]                               Clinical diagnosis                                        11.5%                                            3.8%
  [@bibr20-0004867415575774]                               CIDI                                                      17.0%                                            
  [@bibr23-0004867415575774]                               Clinical diagnosis                                        42.9%                                            
  [@bibr24-0004867415575774]                               Clinical diagnosis                                        28.0%                                            6.0%
  [@bibr27-0004867415575774]                               SCID (DSM-IV)                                             10.4%                                            4.2%
  [@bibr27-0004867415575774]                               SCID (DSM-IV)                        29.5%                13.1%                       6.7%                 
  [@bibr29-0004867415575774]                               SCID (DSM-IV)                        4.8%                                                                  
  [@bibr35-0004867415575774]                               SCID (DSM-III-R)                     8.7%                                                                  
  [@bibr37-0004867415575774]                               Clinical diagnosis (DSM-IV)          12.1%                                                                 
  [@bibr39-0004867415575774]/ [@bibr40-0004867415575774]   Clinical diagnosis                                        42.5%                                            7.1%
  [@bibr42-0004867415575774]                               Clinical diagnosis                                        25.7%                                            
  [@bibr43-0004867415575774]                               MINI                                 82.5%                82.5%                                            20.0%
  [@bibr45-0004867415575774]                               Clinical diagnosis (DSM-III-R)                            11.6%                                            4.7%
  [@bibr49-0004867415575774]                               SCID (DSM-IV)                        11.7%                                                                 
  [@bibr58-0004867415575774]                               MINI                                 83.0%                16.7%                       5.6%                 66.6%
  [@bibr64-0004867415575774]                               Clinical diagnosis (DSM-IV/ICD-10)   18.5%                17.5%                                            
  [@bibr68-0004867415575774]                               SCID (DSM-III-R)                     37.5%                35.0%                       7.5%                 0%
  [@bibr69-0004867415575774]                               Clinical diagnosis (DSM-III-R)       12.0%                                                                 
  [@bibr72-0004867415575774]                               SCAN                                                      45.0%                                            7.5%
  [@bibr73-0004867415575774]                               SCAN                                                      71.4%                                            7.9%
  [@bibr78-0004867415575774]                               SCID (DSM-IV)                                             28.1%                                            
  Summary effect (95% CI)                                                                       23.1% (14.9--34.0)   29.9% (20.5--41.3)          6.7% (4.8--9.2)      8.8% (4.4--17.1)
  *I^2^* (%)                                                                                    94.87                93.73                       0.00                 82.21

![](10.1177_0004867415575774-table4)

BDI: Beck Depression Inventory; CIDI: Composite International Diagnostic Interview; MINI: Mini International Neuropsychiatric Interview; SCAN: Schedules for Clinical Assessment in Neuropsychiatry; SCID (DSM-III-R): Structured Clinical Interview for DSM-III-R; SCID (DSM-IV): Structured Clinical Interview for DSM-IV.

#### Anxiety disorders {#section22-0004867415575774}

Prevalence estimates for anxiety disorders were provided by 15 studies ([Table 5](#table5-0004867415575774){ref-type="table"}). There was a weighted mean effect of 17.6% (95% CI 0.8--27.3) for any anxiety disorder. The anxiety disorders with the highest weighted mean effects were social phobia (14.9%, 95% CI 2.0--59.8) and generalised anxiety disorder (GAD) (14.4%, 95% CI 3.9--40.8), followed by panic disorder (13.7%, 95% CI 6.7--26.0), post-traumatic stress disorder (PTSD) (12.3%, 95% CI 3.4--35.7) and obsessive-compulsive disorder (OCD) (8.2%, 95% CI 3.4--18.6). There was high to very high between-study heterogeneity for current anxiety disorders.

###### 

Prevalence of co-morbid current anxiety disorders in treatment-seeking problem gamblers.

  Study                                                    Co-morbidity measure          Any anxiety disorder   OCD                Panic disorder      GAD                 PTSD                Social phobia
  -------------------------------------------------------- ----------------------------- ---------------------- ------------------ ------------------- ------------------- ------------------- -------------------
  [@bibr13-0004867415575774]                               Clinical diagnosis                                   9.0%               3.8%                3.8%                                    
  [@bibr20-0004867415575774]                               CIDI                          17.0%                                                                                                 
  [@bibr23-0004867415575774]                               Clinical diagnosis                                                      7.1%                                                        7.1%
  [@bibr27-0004867415575774]                               SCID (DSM-IV)                                        2.1%                                                                           
  [@bibr27-0004867415575774]                               SCID (DSM-IV)                 11.4%                                                                                                 
  [@bibr29-0004867415575774]                               SCID (DSM-IV)                 8.6%                                                                                                  
  [@bibr35-0004867415575774]                               SCID (DSM-III-R)              4.3%                                                                                                  
  [@bibr37-0004867415575774]                               Clinical diagnosis (DSM-IV)   10.1%                                                                                                 
  [@bibr39-0004867415575774]/ [@bibr40-0004867415575774]   Clinical diagnosis            7.0%                                                                              5.3%                
  [@bibr43-0004867415575774]                               MINI                          47.5%                  5.0%               27.5%               22.5%                                   
  [@bibr48-0004867415575774]                               PTSD Checklist -- Civilian                                                                                      34.2%               
  [@bibr58-0004867415575774]                               MINI                          94.4%                  50.0%              38.9%               50.0%               16.7%               50.0%
  [@bibr68-0004867415575774]                               SCID (DSM-III-R)              22.5%                  2.5%               10.0%               5.0%                5.0%                5.0%
  [@bibr72-0004867415575774]                               SCAN                          27.5%                  2.5%                                                                           
  [@bibr73-0004867415575774]                               SCAN                                                 14.3%              10.0%                                                       
  Summary effect (95% CI)                                                                17.6% (10.8--27.3)     8.2% (3.4--18.6)   13.7% (6.7--26.0)   14.4% (3.9--40.8)   12.3% (3.4--35.7)   14.9% (2.0--59.8)
  *I^2^* (%)                                                                             88.44                  81.86              77.42               86.98               90.58               85.61

![](10.1177_0004867415575774-table5)

CIDI: Composite International Diagnostic Interview; MINI: Mini International Neuropsychiatric Interview; PTSD Checklist -- Civilian: Post-traumatic Stress Disorder Checklist -- Civilian version; SCAN: Schedules for Clinical Assessment in Neuropsychiatry; SCID (DSM-III-R): Structured Clinical Interview for DSM-III-R; SCID (DSM-IV): Structured Clinical Interview for DSM-IV.

#### Other disorders {#section23-0004867415575774}

Prevalence estimates for other DSM-IV Axis I disorders were provided by 13 studies ([Table 6](#table6-0004867415575774){ref-type="table"}). None of the primary articles employed to derive the prevalence estimate for psychotic disorder reported excluding participants on the basis of conditions that precluded completion of assessment measures or treatment. The highest weighted mean effects were for attention-deficit hyperactivity disorder (ADHD) (9.3%, 95% CI 4.1--19.6) and adjustment disorder (9.2%, 95% CI 4.8--17.2). There was low to very low between-study heterogeneity for all current other disorders, except adjustment disorder and ADHD, which had moderate to high between-study heterogeneity.

###### 

Prevalence of co-morbid current other Axis I disorders in treatment-seeking problem gamblers.

  Study                                                    Co-morbidity measure             Intermittent explosive disorder   Kleptomania       Psychotic disorder   Somatoform disorder   Adjustment disorder   ADHD
  -------------------------------------------------------- -------------------------------- --------------------------------- ----------------- -------------------- --------------------- --------------------- ------------------
  [@bibr13-0004867415575774]                               Clinical diagnosis                                                                                                                                    1.3%
  [@bibr21-0004867415575774]                               ASRS                                                                                                                                                  10.5%
  [@bibr27-0004867415575774]                               MIDI                             2.1%                              2.1%                                                                               
  [@bibr29-0004867415575774]                               SCID (DSM-IV)                                                                        0%                   1.0%                  0%                    
  [@bibr29-0004867415575774]                               MIDI                             4.8%                              1.9%                                                                               
  [@bibr35-0004867415575774]                               SCID (DSM-III-R)                                                                                                                17.4%                 
  [@bibr37-0004867415575774]                               Clinical diagnosis (DSM-IV)                                                          4.2%                                                             
  [@bibr39-0004867415575774]/ [@bibr40-0004867415575774]   Clinical diagnosis                                                                   5.3%                                       15.9%                 
  [@bibr43-0004867415575774]                               MINI                                                                                                      10.0%                 5.0%                  7.5%
  [@bibr47-0004867415575774]                               MCMI-III                                                                             6.0%                                                             
  [@bibr67-0004867415575774]                               Clinical diagnosis                                                                                                                                    20.0%
  [@bibr68-0004867415575774]                               SCID (DSM-III-R)                                                                     2.5%                 0%                                          
  [@bibr68-0004867415575774]                               MIDI                             7.5%                              5.0%                                                                               
  [@bibr69-0004867415575774]                               Clinical diagnosis (DSM-III-R)                                                                                                  7.0%                  
  [@bibr72-0004867415575774]                               SCAN                                                                                                      2.5%                                        
  [@bibr73-0004867415575774]                               SCAN                                                                                                      3.6%                                        
  Summary effect (95% CI)                                                                   4.6% (2.5--8.4)                   2.7% (1.2--5.9)   4.7% (3.4--6.5)      3.6% (1.6--8.0)       9.2% (4.8--17.2)      9.3% (4.1--19.6)
  *I^2^* (%)                                                                                3.22                              0.0               8.81                 39.42                 80.27                 65.30

![](10.1177_0004867415575774-table6)

ASRS: Adult ADHD Self-Report Scale; MCMI-III: Millon Clinical Multiaxial Inventory-III; MIDI: Minnesota Impulsive Disorders Interview; MINI: Mini International Neuropsychiatric Interview; SCAN: Schedules for Clinical Assessment in Neuropsychiatry; SCID (DSM-III-R): Structured Clinical Interview for DSM-III-R; SCID (DSM-IV): Structured Clinical Interview for DSM-IV.

### Lifetime DSM-IV Axis I disorders {#section24-0004867415575774}

Prevalence estimates for lifetime DSM-IV Axis I disorders were provided by 13 studies ([Table 7](#table7-0004867415575774){ref-type="table"}). There was a weighted mean effect of 75.5% (95% CI 45.6--91.8) for lifetime Axis I disorders. There were weighted mean effects of 47.0% (95% CI 31.0--63.7) for any alcohol or substance use disorder, 41.1% (95% CI 29.1--54.2) for any alcohol use disorder, 38.6% (95% CI 25.7--53.4) for any mood disorder, 23.9% (95% CI 16.3--33.8) for any anxiety disorder and 21.4% (95% CI 12.2--34.7) for any substance (non-alcohol) use disorder. There was high to very high between-study heterogeneity for lifetime Axis I disorders.

###### 

Prevalence of co-morbid lifetime Axis I disorders in treatment-seeking problem gamblers.

  Study                                                    Co-morbidity measure   Any Axis I disorder   Any alcohol or substance use disorder   Any alcohol use disorder   Alcohol dependence   Any substance (non-alcohol) use disorder   Any mood disorder    Major depressive disorder   Any anxiety disorder   OCD
  -------------------------------------------------------- ---------------------- --------------------- --------------------------------------- -------------------------- -------------------- ------------------------------------------ -------------------- --------------------------- ---------------------- ------------------
  [@bibr5-0004867415575774]                                CAGE                                                                                                            25.6%                                                                                                                                   
  [@bibr10-0004867415575774]                               SCID (DSM-IV)                                34.0%                                                                                                                                                   70.0%                       25.0%                  
  [@bibr11-0004867415575774]                               DIS-R                                                                                                                                                                                                                                                   15.0%
  [@bibr21-0004867415575774]                               MINI                                                                                 41.5%                                           29.3%                                      42.7%                                            32.9%                  
  [@bibr23-0004867415575774]                               Clinical diagnosis                                                                   35.7%                                                                                                                                                              
  [@bibr27-0004867415575774]                               SCID (DSM-IV)          46.9%                                                         14.6%                                           2.1%                                                            24.0%                                              2.1%
  [@bibr26-0004867415575774]                               SCID (DSM-IV)                                25.2%                                                                                                                              36.3%                                            17.0%                  
  [@bibr29-0004867415575774]                               SCID (DSM-IV)          78.1%                 37.1%                                                                                                                              29.5%                                            30.5%                  
  [@bibr35-0004867415575774]                               SCID (DSM-III-R)                                                                     34.8%                                                                                      15.8%                                            7.2%                   
  [@bibr39-0004867415575774]/ [@bibr40-0004867415575774]   SCID (DSM-IV)                                66.4%                                   59.3%                      42.5%                38.6%                                                                                                              
  [@bibr41-0004867415575774]                               SCID (DSM-IV)                                61.9%                                   55.9%                                           33.6%                                                                                                              
  [@bibr46-0004867415575774]                               SCID (DSM-III-R)                                                                                                47.2%                                                                                                                                   
  [@bibr68-0004867415575774]                               SCID (DSM-III-R)       92.0%                 60.0%                                   50.0%                                           10.0%                                      77.5%                70.0%                       37.5%                  2.5%
  Summary effect (95% CI)                                                         75.5% (45.6--91.8)    47.0% (31.0--63.7)                      41.1% (29.1--54.2)         40.1% (30.4--50.7)   21.4% (12.2--34.7)                         38.6% (25.7--53.4)   54.3% (21.9--83.4)          23.9% (16.3--33.8)     4.8% (1.1--18.0)
  *I^2^* (%)                                                                      93.51                 94.13                                   87.63                      67.08                86.18                                      89.30                94.37                       81.80                  65.37

![](10.1177_0004867415575774-table7)

CAGE: The CAGE Questionnaire; DIS-R: Diagnostic Interview Schedule--Revised; MINI: Mini International Neuropsychiatric Interview; SCID (DSM-III-R): Structured Clinical Interview for DSM-III; SCID (DSM-IV): Structured Clinical Interview for DSM-IV.

Subgroup analyses {#section25-0004867415575774}
-----------------

The potentially relevant sources of heterogeneity identified before the commencement of analysis included: (1) gambling problem severity; (2) the measure of co-morbidity employed; (3) the type of treatment facility; and (4) the jurisdiction in which the study was conducted. Subgroup analyses were performed for the six co-morbid disorders that had sufficient (10 or more) primary studies available (any current alcohol or substance use disorder, any current alcohol use disorder, any current mood disorder, current major depressive disorder, current bipolar disorder and any current anxiety disorder).

### Gambling problem severity {#section26-0004867415575774}

Only alcohol use disorder and major depressive disorder had sufficient primary studies in both gambling problem severity subgroups (pathological gamblers and problem gamblers) to conduct subgroup analyses. For alcohol use disorder, pathological gambling samples (17.3%, 95% CI 11.7--25.0) yielded statistically significantly lower point estimates relative to problem gambling samples (33.1%, 95% CI 27.1--39.7). There was no evidence of systematic variation in point estimates for major depressive disorder.

### Measure of co-morbidity employed {#section27-0004867415575774}

None of the disorders had sufficient primary studies in both co-morbidity measure subgroups (clinician-administered interviews and self-report questionnaires) to conduct subgroup analyses.

### Type of treatment facility {#section28-0004867415575774}

Only major depressive disorder had sufficient primary studies in both treatment facility subgroups (outpatient treatment and residential treatment) to conduct subgroup analyses. There was no evidence of systematic variation in point estimates for this disorder.

### Jurisdiction {#section29-0004867415575774}

All co-morbid disorders except bipolar disorder had sufficient primary studies in both jurisdiction subgroups (US and Europe) to conduct subgroup analyses. Prevalence estimates for alcohol use disorder from studies in the US (13.6%, 95% CI 7.6--23.0) were significantly lower than those from studies conducted in Europe (31.7%, 95% CI 24.8--39.5). However, there was no evidence of systematic variation in point estimates for mood disorder, anxiety disorder, major depressive disorder, or alcohol or substance use disorder.

Risk of bias assessment {#section30-0004867415575774}
-----------------------

A components approach was adopted to assess risk of bias in this systematic review ([Table 8](#table8-0004867415575774){ref-type="table"}). Measurement of co-morbidity was the stated purpose of the study for almost two-thirds of the included studies (61.1%). Almost all (97.2%) employed a valid and reliable gambling measure, and most studies (86.1%) reported that they did not have any sponsorship from the gambling industry. Although most (86.1%) were observational studies of treatment in naturalistic settings (i.e. not clinical trials), the representativeness of the included samples was limited by only 63.9% reporting consecutive or random recruitment of participants. Moreover, only 19.4% of studies reported employing an appropriate comparison group and few studies (5.8%) ruled out any impact from a concurrent intervention or an unintended exposure that might bias results. Just under half of the included studies (44.4%) were classified as having a non-representative sampling bias (self-selected samples and/or clinical trials).

###### 

Risk of bias assessment.

  Study                                                    Purposive   Appropriate comparison group   Consecutive/ random recruitment   Naturalistic treatment   Concurrent treatment restriction   Valid and reliable gambling measure   Gambling industry sponsorship
  -------------------------------------------------------- ----------- ------------------------------ --------------------------------- ------------------------ ---------------------------------- ------------------------------------- -------------------------------
  [@bibr5-0004867415575774]                                Y           N                              N                                 Y                        N                                  Y                                     N
  [@bibr10-0004867415575774]                               N           N                              Y                                 Y                        N                                  Y                                     NR
  [@bibr11-0004867415575774]                               N           Y                              NR                                Y                        Y                                  Y                                     NR
  [@bibr13-0004867415575774]                               Y           N                              NR                                Y                        N                                  Y                                     NR
  [@bibr19-0004867415575774]                               Y           N                              Y                                 Y                        N                                  Y                                     N
  [@bibr20-0004867415575774]                               N           Y                              NR                                Y                        N                                  Y                                     N
  [@bibr21-0004867415575774]                               Y           N                              Y                                 Y                        N                                  Y                                     Y
  [@bibr22-0004867415575774]                               N           N                              Y                                 Y                        N                                  Y                                     N
  [@bibr23-0004867415575774]                               N           N                              Y                                 Y                        N                                  Y                                     N
  [@bibr24-0004867415575774]                               N           N                              Y                                 Y                        N                                  Y                                     N
  [@bibr27-0004867415575774]                               Y           N                              NR                                N                        N                                  Y                                     N
  [@bibr26-0004867415575774]                               Y           N                              Y                                 N                        N                                  Y                                     N
  [@bibr27-0004867415575774]                               Y           N                              Y                                 N                        N                                  Y                                     N
  [@bibr29-0004867415575774]                               Y           N                              Y                                 N                        N                                  Y                                     N
  [@bibr35-0004867415575774]                               Y           N                              Y                                 Y                        N                                  Y                                     N
  [@bibr37-0004867415575774]                               Y           N                              Y                                 Y                        N                                  Y                                     N
  [@bibr39-0004867415575774]/ [@bibr40-0004867415575774]   Y           N                              Y                                 Y                        N                                  Y                                     N
  [@bibr41-0004867415575774]                               Y           Y                              Y                                 Y                        N                                  Y                                     N
  [@bibr42-0004867415575774]                               Y           N                              Y                                 Y                        N                                  Y                                     N
  [@bibr43-0004867415575774]                               Y           N                              N                                 Y                        N                                  Y                                     N
  [@bibr44-0004867415575774]                               N           Y                              NR                                N                        N                                  Y                                     N
  [@bibr45-0004867415575774]                               N           N                              NR                                Y                        N                                  Y                                     NR
  [@bibr46-0004867415575774]                               Y           N                              Y                                 Y                        N                                  Y                                     N
  [@bibr47-0004867415575774]                               Y           N                              N                                 Y                        N                                  Y                                     N
  [@bibr48-0004867415575774]                               Y           N                              N                                 Y                        N                                  Y                                     N
  [@bibr49-0004867415575774]/ [@bibr74-0004867415575774]   Y           N                              Y                                 Y                        N                                  Y                                     N
  [@bibr52-0004867415575774]                               Y           N                              Y                                 Y                        N                                  Y                                     N
  [@bibr54-0004867415575774]                               Y           N                              Y                                 Y                        N                                  Y                                     N
  [@bibr58-0004867415575774]                               Y           Y                              N                                 Y                        N                                  Y                                     N
  [@bibr64-0004867415575774]                               N           N                              Y                                 Y                        N                                  Y                                     N
  [@bibr66-0004867415575774]                               N           N                              Y                                 Y                        N                                  Y                                     N
  [@bibr67-0004867415575774]/ [@bibr68-0004867415575774]   Y           Y                              N                                 Y                        N                                  Y                                     N
  [@bibr69-0004867415575774]                               N           N                              Y                                 Y                        N                                  Y                                     N
  [@bibr72-0004867415575774]                               N           Y                              Y                                 Y                        Y                                  Y                                     N
  [@bibr73-0004867415575774]                               N           N                              Y                                 Y                        N                                  Y                                     N
  [@bibr78-0004867415575774]                               N           N                              NR                                Y                        N                                  NR                                    N

![](10.1177_0004867415575774-table8)

NR: Not reported.

Sensitivity analyses {#section31-0004867415575774}
--------------------

Sensitivity analyses were conducted to determine whether findings were robust to the inclusion of studies with non-representative sampling biases, and involved sequentially limiting studies to: (1) observational studies of treatment in naturalistic settings (i.e. clinical trials were excluded); and (2) random samples or recruitment of consecutive admissions (i.e. self-selected samples or studies failing to indicate sampling strategies were excluded). Given the large number of analyses conducted, these results are available from the corresponding author.

### Studies of naturalistic treatment {#section32-0004867415575774}

Across most types of co-morbidity, results based on studies of naturalistic treatment varied minimally relative to all studies including clinical trials. Where salient differences were observed, they generally indicated higher estimates in analyses of naturalistic treatment. The largest differences were observed for: (1) 'any lifetime Axis I disorder', whereby studies of naturalistic treatment suggested higher estimates (*k=*1; 92.5%, 95% CI 79.2--91.8) relative to results from all studies (*k*=3; 75.5%, 95% CI 45.6--0.92); and (2) 'lifetime major depressive disorder', whereby studies of naturalistic treatment suggested higher estimates (*k*=2; 70.2%, 95% CI 59.7--79.0) relative to results from all studies (*k*=3; 54.3%, 95% CI 21.9--83.4). In each instance, the sensitivity analyses were based on few studies and produced wide 95% CIs. Only the analyses of 'any current impulse control disorder' suggested lower estimates in studies of naturalistic treatment (*k*=3; 6.7%, 95% CI 0.5--48.4) versus all studies (*k*=5; 13.7%, 95% CI 4.2--36.1); however, the magnitude of the difference was small. Accordingly, it was concluded that the results of the review were robust to the inclusion of clinical trials.

### Studies of random samples and consecutive admissions {#section33-0004867415575774}

Across most types of co-morbidity, results based on random samples or consecutive admissions varied minimally relative to analyses based on all studies (including self-selected samples). Where more salient differences were observed, there was no clear pattern of higher or lower estimates. The largest increase was observed for 'lifetime major depressive disorder', whereby studies of random / consecutive samples suggested higher estimates (*k*=2; 70.2%, 95% CI 59.7--79.0) relative to all studies (*k*=3; 54.3%, 95% CI 21.9--83.4). The largest decrease was observed for 'current social phobia' (equal with GAD), whereby studies of random/consecutive samples suggested lower estimates (*k*=2; 5.6%, 95% CI 1.8--16.1) relative to results from all studies (*k*=3; 14.9%, 95% CI 2.0--59.8). In each instance, the sensitivity analyses were based on few studies and produced wide 95% CIs, while the absolute magnitudes of differences were small. Accordingly, it was concluded that results of the current review were also robust to inclusion of self-selected samples.

Discussion {#section34-0004867415575774}
==========

Prevalence rates of co-morbid psychiatric disorders {#section35-0004867415575774}
---------------------------------------------------

This is the first systematic review and meta-analysis to explore the prevalence rates of co-morbid psychiatric disorders in treatment-seeking problem gamblers. The findings from 36 studies indicated that approximately three-quarters of treatment-seeking problem gamblers display current and lifetime co-morbid Axis I disorders. The most common current disorders were nicotine dependence, major depressive disorder, alcohol abuse and dependence, social phobia, GAD, panic disorder, PTSD, cannabis use disorder, ADHD, adjustment disorder, bipolar disorder and OCD, while the most common lifetime disorders were major depressive disorder and alcohol and substance use disorders. Unlike previous narrative reviews, this review used robust, replicable and reliable procedures to systematically identify and synthesise all available evidence, including studies in which the investigation of co-morbidity was not the primary aim, and sheds light on the relative strength and reliability of the evidence for each co-morbid psychiatric disorder. Although the general conclusion that treatment-seeking problem gambling is associated with high rates of mood, anxiety and substance use disorders is generally consistent with those of available narrative reviews ([@bibr59-0004867415575774]; [@bibr68-0004867415575774]; [@bibr76-0004867415575774]), this review adds information about the high co-occurrence of problem gambling and specific disorders with less available evidence, such as social phobia, GAD, PTSD, cannabis use disorder, ADHD, adjustment disorder and dysthymic disorder.

Interestingly, the prevalence estimates derived in this review were not consistently higher than those derived from a meta-analysis of community samples ([@bibr51-0004867415575774]). This contrasts with expectations from treatment-seeking sample selection biases ([@bibr6-0004867415575774]; [@bibr12-0004867415575774]) that treatment-seeking samples include those with the most serious gambling problems and the highest rates of co-morbid psychopathology ([@bibr12-0004867415575774]; [@bibr65-0004867415575774]; [@bibr68-0004867415575774]). It may suggest a paradoxical effect, whereby problem gamblers with co-morbid disorders seek treatment at mental health or addiction services to manage their co-morbid psychopathology rather than at specialist gambling agencies for their gambling problems ([@bibr51-0004867415575774]; [@bibr77-0004867415575774]). This explanation is supported by findings that the rate of problem gambling in mental health, alcohol and drug, family violence and financial counselling services is two to 21 times higher ([@bibr15-0004867415575774], [@bibr16-0004867415575774]) than in the general population ([@bibr36-0004867415575774]). It implies that the co-morbid psychiatric condition may be of more concern than the gambling problem or that gamblers are more aware of their co-morbid symptomatology than their gambling symptomatology. Indeed, a recent population study has found that approximately half of problem gamblers do not self-perceive even a moderate gambling problem ([@bibr71-0004867415575774]). An alternative explanation is that the social acceptability, public awareness and accessibility of mental health or addiction services may be higher than gambling services. There may therefore be a need for these services to routinely screen for problem gambling and have appropriate resources to assess and manage the gambling behaviour of problem gambling clients.

Heterogeneity in prevalence estimates of co-morbid psychiatric disorders {#section36-0004867415575774}
------------------------------------------------------------------------

A strength of this systematic review over previous narrative reviews is that it was able to explore the degree to which prevalence estimates of co-morbidity fluctuate as a function of clinical and methodological considerations. A notable feature of the data was significant variability in the reported rates of many co-morbid psychiatric disorders. Unfortunately, although several potentially relevant methodological and clinical factors that may explain the variations in these estimates were explored, no consistent patterns were identified. This is consistent with a meta-analysis of community-representative samples of problem gamblers ([@bibr51-0004867415575774]).

However, there were a few specific findings from the subgroup analyses that are worth noting. The current review revealed significantly lower estimates for alcohol use disorders in pathological gamblers than problem gamblers and in US studies than European studies. These findings could suggest that pathological gamblers with co-morbid alcohol use disorders are more likely to seek assistance at alcohol treatment services than at gambling agencies ([@bibr51-0004867415575774]; [@bibr76-0004867415575774]) and that problem gamblers with alcohol use disorders in the US may be more likely to seek treatment for alcohol use problems than gambling problems compared to their European counterparts. Alternatively, of course, the findings relating to jurisdictional variances could reflect differences in the provision of gambling treatment services across the US and Europe.

As more studies become available and reporting improves, future updates of this review may consider the effect of these and other sample characteristics (such as gender composition of the sample, problematic gambling activity), measurement factors (such as the method and quality of problem gambling and comorbidity measurement), treatment factors (such as type of treatment delivered) or other methodological considerations (such as sample size and year of publication). Subgroup analysis of other methodological issues considered in the risk of bias assessment could also be analysed as sources of variation that could be included in future updates of this review, such as the purposive nature of the co-morbidity measurement, the influence of sponsorship from the gambling industry, the use of a comparison group, and concurrent treatment restriction.

Limitations of the available evidence base {#section37-0004867415575774}
------------------------------------------

Several limitations of the evidence on which the review is based are noted. First, although most studies were observational studies of treatment in naturalistic settings, only two-thirds of studies reported consecutive or random recruitment of participants. Just under half of the included studies were classified as having a non-representative sampling bias as evidenced by the inclusion of self-selected samples and/or clinical trials. Although a higher degree of sample representativeness is necessary in future research, the sensitivity analyses conducted in the current systematic review suggested that the identified prevalence estimates were robust to the inclusion of clinical trials and self-selected samples.

Second, although all cross-sectional, case-control and cohort studies that examined the prevalence of psychiatric conditions in treatment-seeking problem gamblers were included, less than 20% of studies included healthy control groups. The failure to employ these groups do not allow for conclusions regarding the presence of a psychiatric co-morbidity between the problem gambling group and their non-gambling counterparts. Moreover, most studies were unable to rule out any impact from a concurrent intervention that might bias their results. Future research incorporating healthy control groups and exclusion criteria relating to concurrent interventions will enhance the rigour of future research in this area.

Third, most samples were treated in outpatient or residential facilities, with studies delivered in online or telephone settings predominantly excluded on the basis of employing non-standardised measures of psychiatric co-morbidity or clinical characteristics that are not listed as diagnostic conditions in the DSM-IV. Similarly, while studies exploring self-help treatments, Gamblers Anonymous and pharmacological treatments were not excluded from this review, very few studies administering these treatments were included. Given the increased accessibility and confidentiality provided by telephone counselling services, web-based counselling services and self-help interventions ([@bibr15-0004867415575774], [@bibr16-0004867415575774]; [@bibr61-0004867415575774], [@bibr62-0004867415575774], [@bibr63-0004867415575774]), it will be important for future studies to evaluate the psychiatric co-morbidity of these treatment-seeking gamblers using standardised instruments.

Fourth, the cross-sectional nature of the studies reviewed precludes an explication of the temporal or causal relationship between problem gambling and these co-morbid conditions. Future research exploring the onset and pattern of psychiatric disorders and problem gambling using prospective study designs is therefore needed ([@bibr76-0004867415575774]). The prevalence estimates identified in this review must also be interpreted in the context of an emerging literature indicating that a substantial proportion of treatment-seeking problem gamblers have multiple co-morbid conditions ([@bibr35-0004867415575774]; [@bibr43-0004867415575774]; [@bibr46-0004867415575774]; [@bibr76-0004867415575774]). Because failure to control for other disorders may produce inflated rates of psychiatric co-morbidity ([@bibr3-0004867415575774]), research controlling for multiple co-occurring disorders or using multi-morbidity coefficients ([@bibr4-0004867415575774]) is required.

Finally, there are several other limitations of the existing evidence base that are important in determining the direction of future research. The sample sizes of the included studies are generally small and many do not report important characteristics of the study, such as the problematic gambling activity of the participants, the type of treatment facility or the type of treatment delivered. Moreover, although the larger number of problem gamblers in treatment-seeking samples allows for the investigation of lower prevalence co-morbid disorders ([@bibr76-0004867415575774]), there remain many classes of Axis I psychiatric conditions in the DSM-IV that were not explored by sufficient studies to be included in the review, such as cognitive disorders, dissociative disorders, eating disorders, factitious disorders, sexual and gender identity disorders, and sleep disorders. There were also insufficient studies investigating the prevalence of specific disorders within classes that were well-represented in the available literature, such as anxiety disorders (e.g. specific phobia, acute stress disorder), substance use disorders (e.g. opioid-related disorders, cocaine-related disorders) and impulse control disorders (e.g. pyromania, trichotillomania). Future studies using large samples and rigorous reporting protocols are required to investigate the prevalence of these less common psychiatric disorders.

Clinical implications for practice and research {#section38-0004867415575774}
-----------------------------------------------

Although there are some issues around the precision of the findings in the current review, it is clear that treatment-seeking problem gamblers report generally high rates of psychiatric co-morbidity. The findings of this review therefore highlight the need to undertake systematic and routine screening and comprehensive assessment of co-occurring psychiatric disorders in individuals seeking treatment for gambling problems ([@bibr15-0004867415575774], [@bibr16-0004867415575774]; [@bibr59-0004867415575774]; [@bibr76-0004867415575774]). This can be achieved through comprehensive screening for multiple psychiatric co-morbid disorders or targeted screening for prevalent psychiatric disorders such as alcohol and substance use disorders, mood disorders and anxiety disorders ([@bibr76-0004867415575774]). Clients who screen positively for co-morbid problems will require more extensive diagnostic assessments, an exploration of the ways in which the comorbidity is associated with the gambling problem, and identification of therapeutic needs.

The findings of this review also underscore the need to develop individually tailored case formulations, treatment plans, treatment objectives and individualised intervention approaches for problem gamblers with co-morbid psychiatric conditions. Such recognition of psychiatric co-morbidity could serve to maximize treatment response, enhance client satisfaction, reduce attrition and lower treatment costs ([@bibr47-0004867415575774]). There is also a need for an appropriate clinical response by specialist gambling agencies, such as appropriate referral pathways or a workforce with adequate skills to appropriately manage these disorders ([@bibr59-0004867415575774]; [@bibr68-0004867415575774] [@bibr76-0004867415575774]). The presence of high levels of psychiatric co-morbidity suggests that a multimodal, stepped care approach to gambling treatment may be appropriate, whereby treatment intensity increases with increasing client needs. Such a stepped care approach involves a treatment network that encompasses a continuum of integrated services delivering a broad spectrum of treatment from minimally restrictive to increasingly intensive approaches ([@bibr53-0004867415575774]).

Despite their obvious importance, the implications of co-morbid psychiatric disorders for treatment have received little research attention. Although there is some evidence that psychiatric co-morbidity is associated with poorer outcomes and higher attrition rates ([@bibr18-0004867415575774]; [@bibr32-0004867415575774]; [@bibr55-0004867415575774]), few studies have applied targeted pharmacological ([@bibr7-0004867415575774]; [@bibr28-0004867415575774]; [@bibr33-0004867415575774]) or psychological ([@bibr44-0004867415575774]) treatments to subgroups of problem gamblers with co-occurring psychiatric co-morbidity. Further research is required to evaluate the efficacy of interventions specifically designed for these subgroups of problem gamblers.
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